Mariner’s BridgeBio Pharma BBIO Stock Holding History

Mariner’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$790K	Buy	+10,608	New	+$743K	﹤0.01%	2134
2026 Q1	–	Sell	-4,327	Closed	-$330K	–	3571
2025 Q4	$330K	Buy	+4,327	New	+$284K	﹤0.01%	2760
2025 Q3	–	Sell	-5,417	Closed	-$234K	–	3568
2025 Q2	$234K	Buy	+5,417	New	+$197K	﹤0.01%	2925

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Mariner's BBIO Position: Q2 2026 in Review

Mariner opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 10,608 shares worth $790K. The stake represents ﹤0.01% of the portfolio and ranks #2134 among its holdings. This is a return to the name: Mariner previously reported a position in BBIO as recently as Q4 2025.

Mariner first reported a position in BBIO in Q2 2025 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Mariner held 10,608 shares of BridgeBio Pharma worth $790K as of Q2 2026.
BridgeBio Pharma was a new Mariner position in Q2 2026.
BridgeBio Pharma made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #2134 holding.
Mariner first reported a position in BridgeBio Pharma in Q2 2025 and has held it in 3 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.